Cover Image

Breast cancer chemoprevention

Ivana Sestak, Jack Cuzick
  • Ivana Sestak
    Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom | ivana.sestak@cancer.org.uk
  • Jack Cuzick
    Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Abstract

Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indicate that the SERM raloxifene has similar efficacy to tamoxifen, but leads to fewer endometrial cancers, gynecological symptoms, and thromboembolic events. Results for contralateral tumors in adjuvant trials suggest that aromatase inhibitors may be able to prevent up to 70%–80% of ER-positive breast cancers, and this is currently being investigated in two large prevention trials, one using anastrozole (IBIS-II) and the other exemestane (MAP.3). New agents are needed for receptor negative breast cancer and several possibilities are currently under investigation.

Keywords

Breast cancer - Chemoprevention - Selective oestrogen receptor modulators - Aromatase inhibitors

Full Text:

FULL TEXT
Submitted: 2011-12-18 10:50:57
Published: 2011-12-18 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
506

Views:
FULL TEXT
245

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Ivana Sestak, Jack Cuzick

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185